drugset
drugset / Trial / NCT05903274

JSP191 (briquilimab) in Subjects with LR-MDS

NCT05903274 ↗

Phase 1 Terminated 6 enrolled Jasper Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Timeline

Start
2023-06-19
Primary completion
2024-10-21
Completion
2024-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Briquilimab Monoclonal antibody — Intravenous

Indications

myelodysplastic syndrome